Overseas Congresses

All AACR 2022 WFNOS 2022 ASCO GI 2022 SNO 2021 ASTRO 2021 WCGI 2021 ASCO 2021 AACR 2021 WCLC 2020 SNO 2020 ASTRO 2020 ESMO 2020 ASCO 2020 AACR 2020 ASCO GI 2020

# Title Authors Abstract Number Link Tags
1

Self-assembling nanoparticles: A novel approach for targeted cancer treatment using tumor treating fields

AACR 2022 Preclinical study
Preshita Prafulla Desai, Sunil Prabhu. 299 Link [AACR 2022][Preclinical study]
2

Tumor treating fields enhance cellular drug uptake in mesothelioma cell lines

AACR 2022 Preclinical study MPM
Monica Lupi, Rosy Amodeo, Lavinia Morosi, Laura Mannarino, et al. 380 Link [AACR 2022][Preclinical study][MPM]
3

Blood brain barrier (BBB) disruption by tumor treating fields (TTFields) in a human 3D in vitro model

AACR 2022 Preclinical study
Ellaine Salvador, Almuth F. Kessler, Theresa Köppl, Sebastian Schönhärl, et al. 387 Link [AACR 2022][Preclinical study]
4

Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages

AACR 2022 Preclinical study
Yiftah Barsheshet, Boris Brant, Tali Voloshin, Alexandra Volodin, et al. 1305 Link [AACR 2022][Preclinical study]
5

Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability

AACR 2022 Preclinical study Breast
Bella Koltun, Tali Voloshin, Tal Kan, Lilach Koren, et al. 1801 Link [AACR 2022][Preclinical study][Breast]
6

Tumor treating fields induce DNA damage and apoptosis in medulloblastoma

AACR 2022 Preclinical study CNS
Ryan T. Nitta, Gordon Li. 1833 Link [AACR 2022][Preclinical study][CNS]
7

Transcriptomics analysis for identification of pathways involved in the response to Tumor Treating Fields (TTFields)

AACR 2022 Preclinical study
Kerem Wainer-Katsir, Gitit Lavy-Shahaf, Shiri Davidi, Sara Jacobovitch, et al. 1866 Link [AACR 2022][Preclinical study]
8

Spatial omic changes of malignant pleural mesothelioma following treatment using tumor-treating fields

AACR 2022 Preclinical study MPM
Emil Lou, Katherine Ladner, Kerem Wainer-Katsir, Karina Deniz, et al. 2037 Link [AACR 2022][Preclinical study][MPM]
9

Synergic antitumoral activity of TTFields stimulation and Chloride Intracellular Channel 1 (CLIC1) inhibition in human glioblastoma primary culture

AACR 2022 Preclinical study
Michele Mazzanti, Stefania Castiglione, Matteo Ranucci, Gaetano Cannavale, et al. 2315 Link [AACR 2022][Preclinical study]
10

Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors

AACR 2022 Preclinical study Ovary
Antonia Martinez-Conde, Eyal Dor-On, Adi Haber, Moshe Giladi, et al. 2601 Link [AACR 2022][Preclinical study][Ovary]
11

Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields)

AACR 2022 Preclinical study
Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer-Tov, Rom Paz, et al. 2659 Link [AACR 2022][Preclinical study]
12

Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction

AACR 2022 Preclinical study
Alexander Rühle, Maren Strack, Anca-Ligia Grosu, Nils H. Nicolay. 3156 Link [AACR 2022][Preclinical study]
13

Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity

AACR 2022 Preclinical study CNS
Ping Shi, Jia Tian, Brittany Ulm, Julianne Mallinger, et al. 3252 Link [AACR 2022][Preclinical study][CNS]
14

Tumor Treating Fields in combination with radiation cause significant delay in tumor growth in in-vivo mice model significant delay in tumor growth in in-vivo mice model

AACR 2022 Preclinical study
Narasimha Kumar Karanam, Zengfu Shang, Michael D. Story, Debabrata Saha. 3316 Link [AACR 2022][Preclinical study]
15

Tumor treating fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

AACR 2022 Physics / Simulation CNS
Jennifer De Los Santos, Smadar Arvatz, Oshrit Zeevi, Shay Levi, et al. 3447 Link [AACR 2022][Physics / Simulation][CNS]
16

Impact of model inaccuracy on dose estimation in TTFields therapy

AACR 2022 Physics / Simulation CNS
Tal Marciano, Oshrit Zeevi, Zeev Bomzon. 3450 Link [AACR 2022][Physics / Simulation][CNS]
17

Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro

AACR 2022 Preclinical study CNS
Hila Fishman, Roni Monin, Eyal Dor-On, Adi Haber, et al. 3465 Link [AACR 2022][Preclinical study][CNS]
18

PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma

AACR 2022 TiP Pancreas
Vincent J. Picozzi, Judith Finlay, Teresa Macarulla, Philip A. Philip, et al. CT234 Link [AACR 2022][TiP][Pancreas]
19

Breaching the blood brain barrier (BBB) by Tumor Treating Fields (TTFields) could be a novel chemotherapeutic delivery strategy

WFNOS 2022 Preclinical study
Salvador E, Kessler AF, Domroese D, Hoermann J, et al. F-1029 Link [WFNOS 2022][Preclinical study]
20

Effect of duty cycles of tumor-treating fields on glioblastoma cell and normal brain organoids

WFNOS 2022 Preclinical study CNS
Yang SH, Park SM. F-1039 Link [WFNOS 2022][Preclinical study][CNS]
21

Tumor treating fields combined with concurrent radiotherapy for newly diagnosed glioblastoma with rapid early tumor progression

WFNOS 2022 RWE CNS
Wang Z, Du F, Ren Y, Jiang W. F-1061 Link [WFNOS 2022][RWE][CNS]
22

PriCoTTF trial: a phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

WFNOS 2022 Clinical trial CNS
Glas M, Kebir S, Pierscianek D, Proescholdt M, et al. F-1066 Link [WFNOS 2022][Clinical trial][CNS]
23

Synergic antitumoral activity of TTFields stimulation and Chloride Intracellular Channel 1 (CLIC1) inhibition in human glioblastoma primary culture

WFNOS 2022 Preclinical study CNS
Castiglione S, Verduci I, Cianci F, Cannavale G, et al. F-1081 Link [WFNOS 2022][Preclinical study][CNS]
24

Enhancing membrane permeability of cancer cells through delivery of Tumor Treating Fields (TTFields)

WFNOS 2022 Preclinical study
Giladi M, Koltun B, Voloshin T, Kan T, et al. F-1082 Link [WFNOS 2022][Preclinical study]
25

Inhibition of PI3K restores cancer cell sensitivity to Tumor Treating Fields (TTFields)

WFNOS 2022 Preclinical study
Giladi M, Klein-Goldberg A, Voloshin T, Zemer-Tov E, et al. F-1083 Link [WFNOS 2022][Preclinical study]
26

Effects of Tumor Treating Fields in combination with temozolomide and lomustine on glioblastoma cancer cells in vitro

WFNOS 2022 Preclinical study CNS
Giladi M, Fishman H, Dor-On E, Haber A, et al. F-1084 Link [WFNOS 2022][Preclinical study][CNS]
27

Risk assessment scale of scalp adverse events prior to TTFields

WFNOS 2022 RWE
Zhong L, Fan X, Deng L. F-1097 Link [WFNOS 2022][RWE]
28

Trident phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma

WFNOS 2022 TiP CNS
Shi W, Kleinberg L, Jeyapalan S, Goldlust SA, et al. F-1106 Link [WFNOS 2022][TiP][CNS]
29

Final estimates of french health utilities for glioblastoma patients using ttfields

WFNOS 2022 HEOR CNS
Palmer J, Chavez G, Proescholdt C, Furnback W, et al. F-1139 Link [WFNOS 2022][HEOR][CNS]
30

Retrospective analysis of using radiotherapy with concurrent Temozolomide and Tumor Treating Fields for chinese patients with newly diagnosed glioblastoma

WFNOS 2022 RWE CNS
Liang L, Wang Y, Sheng X, Ni C, et al. F-1146 Link [WFNOS 2022][RWE][CNS]
31

Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

WFNOS 2022 Clinical trial CNS
Tran D, Ghiaseddin A, Chen D, Rahman M. F-1182 Link [WFNOS 2022][Clinical trial][CNS]
32

DNA damage response inhibitor combinations to enhance TTFields potency using clinically relevant ex-vivo glioblastoma models

WFNOS 2022 Preclinical study CNS
Vanderlinden A, McGarrity-Cottrell C, Myers K, Carroll TA, et al. F-1187 Link [WFNOS 2022][Preclinical study][CNS]
33

Prostaglandin E receptor 3 mediates resistance to Tumor Treating Fields in glioblastoma cells

WFNOS 2022 Preclinical study CNS
Tran D, Chen D, Le S, Hutchinson T. F-1190 Link [WFNOS 2022][Preclinical study][CNS]
34

Induction of anti-tumor immunity by Tumor Treating Fields (TTFields) in glioblastoma

WFNOS 2022 Preclinical study CNS
Tran D, Chen D, Le S, Hutchinson T, et al. F-1191 Link [WFNOS 2022][Preclinical study][CNS]
35

Real-world retrospective analysis of tumor treating fields in the treatment of high-grade glioma based on chinese population

WFNOS 2022 RWE CNS
Chen L, Chen J, Yao Y, Zhuang D, et al. F-1203 Link [WFNOS 2022][RWE][CNS]
36

Synergistic effect by targeting TTFields induced cell cycle effects

WFNOS 2022 Preclinical study CNS
Slangen P, Tellingen OV, Gooijer MD, Borst G. F-1249 Link [WFNOS 2022][Preclinical study][CNS]
37

Tumor Treating Fields (TTFields) impair the survival and migratory potential of human mesenchymal stromal cells

WFNOS 2022 Preclinical study CNS
Ruehle A, Strack M, Grosu AL, Nicolay NH. F-1258 Link [WFNOS 2022][Preclinical study][CNS]
38

Validating skullremodeling surgery configuration to enhance TTFields for first recurrence glioblastoma with computational modeling

WFNOS 2022 Physics / Simulation CNS
Mikic N, Cao F, Hansen FL, Thielscher A, et al. F-1282 Link [WFNOS 2022][Physics / Simulation][CNS]
39

Tolerability of Tumor Treating Fields (TTFields) in pediatric high-grade glioma patients illustrated by post-market surveillance data

WFNOS 2022 RWE CNS Pediatric
Goldman S. F-1351 Link [WFNOS 2022][RWE][CNS][Pediatric]
40

Feasibility and safety of TTFields therapy for glioblastoma patients with ventriculoperitoneal shunt

WFNOS 2022 RWE CNS
Oberheim-Bush NA, Shi W, McDermott MW, Grote A, et al. F-1353 Link [WFNOS 2022][RWE][CNS]
41

Telehealth to overcome pandemic/geographic barriers: experience managing care of patients with glioblastoma (GBM) receiving Tumor Treating Fields (TTFields) therapy

WFNOS 2022 RWE CNS
Gwyn PG, Frongillo P, Thomas A, Wagenknecht C. F-1358 Link [WFNOS 2022][RWE][CNS]
42

Factors guiding the initiation of Tumor Treating Fields (TTFields; 200 kHz) therapy for glioblastoma: self-reported patient and oncologist perspectives

WFNOS 2022 RWE CNS
Frongillo P, Gwyn PG, Wagenknecht C, Thomas A, et al. F-1362 Link [WFNOS 2022][RWE][CNS]
43

SPARE trial: scalp sparing radiation with concurrent temozolomide and Tumor Treating Fields (200 kHz) for patients with newly diagnosed glioblastoma

WFNOS 2022 Clinical trial CNS
Shi W, Miller R, Song A, Ali A, et al. F-1378 Link [WFNOS 2022][Clinical trial][CNS]
44

Computational anatomic analysis to evaluate the impact of Tumor Treating Fields (TTFields) on brain anatomy

WFNOS 2022 Physics / Simulation CNS
Hottinger AF, Lutti A, Dupuis E, Demicheli R, et al. F-1384 Link [WFNOS 2022][Physics / Simulation][CNS]
45

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

WFNOS 2022 Clinical trial CNS
Shi W, Ali A, Niazi M, Bar-Ad V, et al. F-1386 Link [WFNOS 2022][Clinical trial][CNS]
46

Tumour treating fields (TTFields) therapy for glioblastoma: a quantitative and qualitative summary of research and advances in our understanding

WFNOS 2022 CNS
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, et al. F-1388 Link [WFNOS 2022][CNS]
47

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: secondary analysis of a pilot clinical trial

WFNOS 2022 Clinical trial CNS
Shi W, Taylor J, Miller R, Ali A, et al. F-1389 Link [WFNOS 2022][Clinical trial][CNS]
48

Evidence that recurrence patterns of TTFields treated patients affect patient outcomes: post-hoc analysis of the randomized phase 3 EF-14 trial

WFNOS 2022 Clinical trial CNS
Glas M, Urman N, BomzonZe’ev, Levi S, et al. F-1421 Link [WFNOS 2022][Clinical trial][CNS]
49

Safety and efficacy of TTFields for newly diagnosed GBM in Japanese patients using the Novo-TTF System: a prospective post-approval study

WFNOS 2022 RWE CNS
Nishikawa R, Yamasaki F, Arakawa Y, Muragaki Y, et al. F-2463 Link [WFNOS 2022][RWE][CNS]
50

Developing the framework for Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

WFNOS 2022 Physics / Simulation CNS
Santos JD, Arvatz S, Zeevi O, Levi S, et al. F-2606 Link [WFNOS 2022][Physics / Simulation][CNS]
51

Mechanism of action and associated effects of Tumor Treating Fields (TTFields) on living cells using simulations

WFNOS 2022 Physics / Simulation
Marciano T, Levi S, Fedorov E. F-2608 Link [WFNOS 2022][Physics / Simulation]
52

Combination of Tumor Treating Fields (TTFields) with lomustine and temozolomide - a multicentric real world analysis in newly diagnosed glioblastoma

WFNOS 2022 RWE CNS
Lazaridis L, Schmidt T, Agkatsev S, Seidel C, et al. F-2735 Link [WFNOS 2022][RWE][CNS]
53

Patient-oriented communication strategies improve acceptance of tumour-treating fields in primary and recurrent glioblastoma

WFNOS 2022 RWE CNS
McLean AL, Walter J. F-2740 Link [WFNOS 2022][RWE][CNS]
54

Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo

ASCO GI 2022 Preclinical study Liver
Wyatt Potter, Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al. 464 Link [ASCO GI 2022][Preclinical study][Liver]
55

PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma

ASCO GI 2022 TiP Pancreas
Vincent J. Picozzi, Teresa Macarulla, Philip A. Philip, Carlos Roberto Becerra, et al. TPS629 Link [ASCO GI 2022][TiP][Pancreas]
56

In vitro Tumor Treating Fields (TTFields) reduce proliferation and alter MLH1 expression in temozolomide resistant (TMZR) patient-derived glioblastoma (GBM) cells

SNO 2021 Preclinical study CNS
Sharon Michelhaugh, Katherine Degen, Blake Walker, Sandeep Mittal. CBIO-02 Link [SNO 2021][Preclinical study][CNS]
57

Assessment of Tumor Treating Fields (TTFields) combined with trichostatin A (TSA) in patient-derived glioblastoma (GBM) cells

SNO 2021 Preclinical study CNS
Manxiu Ma, Sharon Michelhaugh, Sandeep Mittal. CSIG-09 Link [SNO 2021][Preclinical study][CNS]
58

Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

SNO 2021 Clinical trial CNS
David Tran, Ashley Ghinaseddin, Dongjiang Chen, Maryam Rahman. CTIM-16 Link [SNO 2021][Clinical trial][CNS]
59

TRIDENT phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly-diagnosed glioblastoma

SNO 2021 TiP CNS
Wenyin Shi, Lawrence Kleinberg, Suriya Jeyapalan, Samuel Goldlust, et al. CTNI-09 Link [SNO 2021][TiP][CNS]
60

Tumor-Treating Fields Combined with Second-line Chemotherapy in Recurrent Glioblastoma: A Matched Retrospective Study

SNO 2021 RWE CNS
Yonggao Mou, Yang Qun-ying, Cheng-Cheng Guo, Meiling Deng, et al. CTNI-11 Link [SNO 2021][RWE][CNS]
61

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

SNO 2021 Clinical trial CNS
Ayesha S Ali, Muneeb Niazi, Voichita Bar-Ad, Maria Werner-Wasik, et al. CTNI-19 Link [SNO 2021][Clinical trial][CNS]
62

PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

SNO 2021 TiP CNS
Sied Kebir, Daniela Pierscianek, Martin Proescholdt, Peter Hau, et al. CTNI-38 Link [SNO 2021][TiP][CNS]
63

Dosimetric impact of tumor treating fields on concurrent radiation therapy for pediatric brain tumors

SNO 2021 Physics / Simulation CNS Pediatric
Enzhuo Quan, Eun Han, Christine Chung, Tina Briere, et al. CTNI-44 Link [SNO 2021][Physics / Simulation][CNS][Pediatric]
64

Retrospective Analysis of Using Radiotherapy with Concurrent Temozolomide and Tumor Treating Fields for Chinese Patients with Newly Diagnosed Glioblastoma

SNO 2021 RWE CNS
Yang Wang, Jingsong Wu, Zhiyong Qin, Enmin Wang, et al. CTNI-52 Link [SNO 2021][RWE][CNS]
65

Prostaglandin E receptor 3 (PTGER3) regulates resistance to Tumor Treating Fields (TTFields) in glioblastoma cells

SNO 2021 Preclinical study CNS
Dongjiang Chen, Son Le, Tarun Hutchinson, David Tran. DDRE-13 Link [SNO 2021][Preclinical study][CNS]
66

Reduced cancer cell sensitivity to Tumor Treating Fields (TTFields) through activation of the PI3K/AKT/mTOR signaling pathway can be mitigated using PI3K inhibitors or PI3K/mTOR dual inhibitors

SNO 2021 Preclinical study
Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer-Tov, Rom Paz, et al. DDRE-46 Link [SNO 2021][Preclinical study]
67

Tumor Treating Fields in combination with the TERT-inhibitor eribulin have synergistic antiproliferative effects on human glioblastoma cells

SNO 2021 Preclinical study CNS
Marco Stein, Piet Beusker, Hanna Goett, Malgorzata Kolodziej, et al. EXTH-05 Link [SNO 2021][Preclinical study][CNS]
68

Increasing cancer cell membrane permeability through application of Tumor Treating Fields (TTFields)

SNO 2021 Preclinical study
Tali Voloshin, Bella Koltun, Lilach Koren, Yaara Porat, et al. EXTH-74 Link [SNO 2021][Preclinical study]
69

Application of Tumor Treating Fields (TTFields) to the head and torso of mice with the dedicated inovivo system

SNO 2021 Preclinical study
Shiri Davidi, Roni Blatt, Mijal Munster, Anna Shteingauz, et al. EXTH-75 Link [SNO 2021][Preclinical study]
70

Developing the novel combination therapy options for cancer therapy using Tumor Treating Fields together with the chemo agents targeting the replication stress pathway

SNO 2021 Preclinical study
Narasimha Kumar Karanam, Michael Story. EXTH-76 Link [SNO 2021][Preclinical study]
71

Induction of Anti-Tumor Immunity by Tumor Treating Fields (TTFields) in Glioblastoma

SNO 2021 Preclinical study CNS
Dongjiang Chen, Son Le, Tarun Hutchinson, Dan Jin, et al. IMMU-35 Link [SNO 2021][Preclinical study][CNS]
72

TTFields Treatment of Gliosarcoma and Recurrent Anaplastic Oligodendroglioma

SNO 2021 Case study CNS
Nicholas Blondin, Robert Fulbright, Anita Huttner, Jennifer Moliterno-Gunel. INNV-07 Link [SNO 2021][Case study][CNS]
73

Tumor treating fields (TTF) as maintenance therapy for an oligodendroglioma case and long-term follow-up

SNO 2021 Case study CNS
Uvin Ko, Steven Du, Matthew Moldenhauer, Xiao-Tang Kong. INNV-10 Link [SNO 2021][Case study][CNS]
74

Understanding factors that influence the decision of accepting Tumor Treating Fields (TTF) therapy

SNO 2021 RWE CNS
Priya Kumthekar, Madison Lyleroehr, Leilani Lacson, Roger Stupp, et al. INNV-13 Link [SNO 2021][RWE][CNS]
75

Effect of duration of Tumor Treating Fields therapy on cellularity distributions beyond T1w MRI contrast enhancing margin at autopsy in glioma patients: preliminary results

SNO 2021 RWE CNS
Samuel Bobholz, Allison Lowman, Michael Brehler, John Sherman, et al. INNV-18 Link [SNO 2021][RWE][CNS]
76

Factors Guiding the Initiation of Tumor Treating Fields (TTFields; 200 kHz) Therapy for Glioblastoma: Self-reported Patient and Oncologist Perspectives

SNO 2021 RWE CNS
Peggy Frongillo, P Gage Gwyn, Connie Wagenknecht, Nichelle Renae Adams. INNV-22 Link [SNO 2021][RWE][CNS]
77

Real-World Retrospective Analysis of Tumor Treating Fields in The Treatment of High-Grade Glioma Based on Chinese Population

SNO 2021 RWE CNS
Lingchao Chen, Junrui Chen, Kun Song, Jingtao Nie, et al. NCOG-14 Link [SNO 2021][RWE][CNS]
78

Delayed pseudoprogression in glioblastoma patients treated with TTFields: A report of two cases

SNO 2021 Case study CNS
Norihiko Saito, Nozomi Hirai, Akinori Yagihashi, Shusaku Takahagi, et al. NIMG-34 Link [SNO 2021][Case study][CNS]
79

A Longitudinal Observational Study of Exercise Behavior in Glioblastoma Patients Treated with Tumor-Treating Fields

SNO 2021 RWE CNS
Katherine Peters, Mary Affronti, Jung-Young Kim, Mallika Patel, et al. QOLP-10 Link [SNO 2021][RWE][CNS]
80

Quality of life of patients with newly diagnosed glioblastoma during TTFields therapy in routine clinical care: first results of the TIGER study

SNO 2021 RWE CNS
Oliver Bähr, Ghazaleh Tabatabai, Rainer Fietkau, Roland Goldbrunner, et al. QOLP-31 Link [SNO 2021][RWE][CNS]
81

SPARE trial: Scalp-sparing radiation with concurrent temozolomide and Tumor Treating Fields for patients with newly diagnosed glioblastoma

SNO 2021 Clinical trial CNS
Ryan Miller, Andrew Song, Ayesha S Ali, Voichita Bar-Ad, et al. RADT-13 Link [SNO 2021][Clinical trial][CNS]
82

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: analysis of a pilot clinical trial

SNO 2021 Clinical trial CNS
Muneeb Niazi, James Taylor, Ryan Miller, Ayesha S Ali, et al. RADT-22 Link [SNO 2021][Clinical trial][CNS]
83

Developing the framework for Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

SNO 2021 Physics / Simulation CNS
Jennifer de Los Santos, Smadar Arvatz, Oshrit Zeevi, Shay Levi, et al. RBIO-01 Link [SNO 2021][Physics / Simulation][CNS]
84

Mechanism of action and associated effects of Tumor Treating Fields (TTFields) on living cells using simulations

SNO 2021 Physics / Simulation
Tal Marciano, Shay Levi, Eduard Fedorov. RBIO-06 Link [SNO 2021][Physics / Simulation]
85

The safety profile of Tumor Treating Fields (TTFields; 200 kHz) concomitant with ventriculo-peritoneal shunts in patients with glioblastoma and hydrocephalus

SNO 2021 RWE CNS
Nancy Ann Oberheim-Bush, Wenyin Shi, Michael McDermott, Alexander Grote, et al. SURG-06 Link [SNO 2021][RWE][CNS]
86

Mechanism of action of Tumor Treating Fields (TTFields) in combination with sorafenib for treatment of hepatocellular carcinoma

ASTRO 2021 Preclinical study Liver
S Davidi, A Shteingauz, S Jacobovitch, K Gotlib, et al. 2045 Link [ASTRO 2021][Preclinical study][Liver]
87

Comprehensive approaches to enhancing Tumor Treating Fields dose at the tumor

ASTRO 2021 Physics / Simulation CNS
Z Bomzon, N Urman, A Naveh, T Marciano, et al. 2250 Link [ASTRO 2021][Physics / Simulation][CNS]
88

Framework for dosimetry and treatment planning of TTFields

ASTRO 2021 Physics / Simulation CNS
Z Bomzon, B Berger, N Urman, O Bakalo, et al. 2251 Link [ASTRO 2021][Physics / Simulation][CNS]
89

Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

ASTRO 2021 Physics / Simulation CNS
JF De Los Santos, S Arvatz, O Zeevi, S Levi, et al. 2252 Link [ASTRO 2021][Physics / Simulation][CNS]
90

Creating computational models for planning TTFields treatment for tumors in the infratentorial brain

ASTRO 2021 Physics / Simulation CNS
Y Glozman, R Faran, R Shamir, B Berger, et al. 2253 Link [ASTRO 2021][Physics / Simulation][CNS]
91

Impact of model inaccuracy on dose estimation in TTFields therapy

ASTRO 2021 Physics / Simulation CNS
T Marciano, O Zeevi, Z Bomzon. 2257 Link [ASTRO 2021][Physics / Simulation][CNS]
92

Treating spinal-cord tumors with TTFields — A simulation study

ASTRO 2021 Physics / Simulation CNS
A Naveh, T Marciano, Z Bomzon, D Divlianska, et al. 2258 Link [ASTRO 2021][Physics / Simulation][CNS]
93

Segmentation of the upper torso for lung cancer TTFields treatment planning

ASTRO 2021 Physics / Simulation Lung
O Peles, H Ben Atya, R Shamir, B Berger, et al. 2259 Link [ASTRO 2021][Physics / Simulation][Lung]
94

Tumor Treating Fields synergistically enhances cell death in non-small cell lung and pancreatic cancer cells treated with the combination of radiation and chemo agents that interfere with DNA replication fork stability

ASTRO 2021 Preclinical study Lung Pancreas
NK Karanam, MD Story. 2454 Link [ASTRO 2021][Preclinical study][Lung][Pancreas]
95

Activated phosphoinositide 3-kinase/AKT/mTOR signaling confers resistance to Tumor Treating Fields (TTFields)

ASTRO 2021 Preclinical study
A Klein-Goldberg, T Voloshin, E Zemer-Tov, R Paz, et al. 2504 Link [ASTRO 2021][Preclinical study]
96

Impact of Tumor Treating Fields (TTFields) on DNA damage repair in mesothelioma

ASTRO 2021 Preclinical study MPM
H Mumblat, A Martinez-Conde, O Braten, M Munster, et al. 2960 Link [ASTRO 2021][Preclinical study][MPM]
97

SPARE trial: Scalp sparing radiation with concurrent temozolomide and Tumor Treating Fields (200 kHz) for patients with newly diagnosed glioblastoma

ASTRO 2021 Clinical trial CNS
RC Miller, AJ Song, A Ali, V Bar-Ad, et al. 3252 Link [ASTRO 2021][Clinical trial][CNS]
98

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

ASTRO 2021 Clinical trial CNS
A Ali, MZK Niazi, V Bar-Ad, M Werner-Wasik, et al. 3255 Link [ASTRO 2021][Clinical trial][CNS]
99

Combination treatment of irradiation and Tumor Treating Fields for human glioblastoma cells

ASTRO 2021 Preclinical study CNS
M Stein, P Beusker, H Goett, M Kolodziej, et al. 3264 Link [ASTRO 2021][Preclinical study][CNS]
100

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: Analysis of a pilot clinical trial

ASTRO 2021 Clinical trial CNS
J Taylor, RC Miller, A Ali, V Bar-Ad, et al. 3268 Link [ASTRO 2021][Clinical trial][CNS]
101

HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma

WCGI 2021 Clinical trial Liver
E. Gkika, A. Grosu, T. Macarulla, A. Cubillo, et al. O-16 Link [WCGI 2021][Clinical trial][Liver]
102

Underlining mechanism for the efficacy of Tumor Treating Fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma

WCGI 2021 Preclinical study Liver
S. Davidi, S. Jacobovitch, A. Shteingauz, C. Tempel-Brami, et al. P-184 Link [WCGI 2021][Preclinical study][Liver]
103

Health-related quality of life for glioblastoma short and long-term survivors receiving treatment with TTFields

ASCO 2021 RWE CNS
Joshua David Palmer, Po-Ya Chuang, Gordon Chavez, Bruce CM Wang, Christina Proescholdt. 2055 Link [ASCO 2021][RWE][CNS]
104

Scalp-sparing radiation with concurrent temozolomide and Tumor Treating Fields (SPARE) for patients with newly diagnosed glioblastoma

ASCO 2021 Clinical trial CNS
Ryan C Miller, Andrew Jehyun Song, Ayesha Ali, Voichita C Bar-Ad, Nina Leyson Martinez, et al. 2056 Link [ASCO 2021][Clinical trial][CNS]
105

Transient opening of the blood brain barrier by Tumor Treating Fields (TTFields)

AACR 2021 Preclinical study CNS
Catherine Tempel Brami, Ellaine Salvador, Almuth F. Kessler, Malgorzata Burek, Tali Voloshin, et al. 279 Link [AACR 2021][Preclinical study][CNS]
106

Rapid transformation of TTFields care-delivery during COVID-19 pandemic to optimize treatment of patients with glioblastoma (GBM)

AACR 2021 CNS
Peggy M. Frongillo, Melissa Shackelford, Lindsay Rain. 717 Link [AACR 2021][CNS]
107

Patient-derived metastatic renal carcinoma cells are highly sensitive to in vitro Tumor Treating Fields (TTFields)

AACR 2021 Preclinical study Kidney
Sharon K. Michelhaugh, Blake C. Walker, Susan Coombe, Sandeep Mittal. 1007 Link [AACR 2021][Preclinical study][Kidney]
108

Valproic acid (VPA) combined with Tumor Treating Fields (TTFields) in vitro decreases cellular proliferation and increases clonogenic potential of glioblastoma (GBM) cells

AACR 2021 Preclinical study CNS
Sharon K. Michelhaugh, Susan Coombe, Katherine E. Degen, Sandeep Mittal. 1037 Link [AACR 2021][Preclinical study][CNS]
109

Targeting replication stress pathway provides an avenue for novel combination therapy options including TTFields plus chemo agents which increase replication stress

AACR 2021 Preclinical study
Narasimha Kumar Karanam, Michael Dean Story. 1051 Link [AACR 2021][Preclinical study]
110

Effectiveness of Tumor Treating Fields (TTFields) in combination with sorafenib for treatment of hepatocellular carcinoma in vitro and in vivo

AACR 2021 Preclinical study Liver
Shiri Davidi, Anna Shteingauz, Sara Jacobovitch, Karnit Gotlib, Catherine Tempel-Brami, et al. 1063 Link [AACR 2021][Preclinical study][Liver]
111

Antiproliferative effects of Tumor Treating Fields in human mesothelioma cell lines

AACR 2021 Preclinical study MPM
Monica Lupi, Federica Mirimao, Nicolò Panini, Greta Piazza, Lara Paracchini, et al. 1064 Link [AACR 2021][Preclinical study][MPM]
112

Concomitant dexamethasone treatment and Tumor Treating Fields induced cell death in glioblastoma

AACR 2021 Preclinical study CNS
Abigail Schiesl, Benedikt Linder, Franz Rödel, Stephanie Hehlgans, Ömer Güllülü, et al. 1065 Link [AACR 2021][Preclinical study][CNS]
113

Efficacy of Tumor Treating Fields (TTFields) in mesothelioma is associated with reduced capacity for DNA damage repair

AACR 2021 Preclinical study MPM
Helena Mumblat, Antonia Martinez, Ori Braten, Mijal Munster, Eyal Dor-On, et al. 1186 Link [AACR 2021][Preclinical study][MPM]
114

Long-duration term TTFields treatment of glioblastoma cells induces cell death

AACR 2021 Preclinical study CNS
Stefania Castiglione, Matteo Ranucci, Gaetano Cannavale, Francesca Cianci, Ivan Verduci, et al. 1200 Link [AACR 2021][Preclinical study][CNS]
115

inovivo: a dedicated system for delivery of therapeutic level Tumor Treating Fields (TTFields) to mice

AACR 2021 Preclinical study
Shiri Davidi, Roni Blatt, Mijal Munster, Anna Shteingauz, Yaara Porat, et al. 1317 Link [AACR 2021][Preclinical study]
116

Targeting Akt signaling pathway potentiates the antitumor effect of Tumor Treating Fields (TTFields) in vitro

AACR 2021 Preclinical study
Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer-Tov, Rom Paz, Lilach Koren, et al. 1382 Link [AACR 2021][Preclinical study]
117

The distribution of Tumor Treating Fields is affected by cell confluence and pores in the membrane

AACR 2021 Physics / Simulation
Tal Marciano, Shay Levi, Eduard Fedorov, Zeev Bomzon. 1435 Link [AACR 2021][Physics / Simulation]
118

A novel immunoregulatory role of tumor Treating Fields (TTFields) on macrophage polarization

AACR 2021 Preclinical study
Boris Brant, Tali Voloshin, Alexandra Volodin, Lilach Koren, Anat Klein-Goldberg, et al. 1692 Link [AACR 2021][Preclinical study]
119

Tumor Treating Fields triggers OFD1 removal from primary cilia to promote glioma cell survival

AACR 2021 Preclinical study CNS
Ping Shi, Jia Tian, Matthew R. Sarkisian. 1975 Link [AACR 2021][Preclinical study][CNS]
120

Tumor Treating Fields induce cellular and morphologic changes including disruption of intercellular communication networks in malignant pleural mesothelioma

AACR 2021 Preclinical study MPM
Akshat Sarkari, Sophie Korenfeld, Katherine Ladner, Phillip Wong, Antonia Martinez, et al. 2011 Link [AACR 2021][Preclinical study][MPM]
121

French health utilities for patients with glioblastoma using TTFields

AACR 2021 HEOR CNS
Gordon V. Chavez, Christina Proescholdt. 2634 Link [AACR 2021][HEOR][CNS]
122

Contemporary clinical practice guidelines for the management of glioblastoma: an international survey

AACR 2021 CNS
Aaron Lawson McLean, Jan Walter. 2635 Link [AACR 2021][CNS]
123

Tumor Treating Fields induce DNA damage and apoptosis in medulloblastoma

AACR 2021 Preclinical study CNS
Ryan T. Nitta, Gordon Li. 3049 Link [AACR 2021][Preclinical study][CNS]
124

Lung cancer TTFields treatment planning sensitivity to errors in torso segmentation

AACR 2021 Physics / Simulation Lung
Hadas Ben Atya, Oren Peles, Reuben Shamir, Zeev Bomzon. 3070 Link [AACR 2021][Physics / Simulation][Lung]
125

A method for infratentorial structures segmentation for Tumor Treating Fields treatment planning

AACR 2021 Physics / Simulation CNS
Yana Glozman, Reuben R. Shamir, Zeev Bomzon. 3071 Link [AACR 2021][Physics / Simulation][CNS]
126

EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

AACR 2021 TiP CNS
Wenyin Shi, Lawrence Kleinberg, Suriya A. Jeyapalan, Samuel A. Goldlust, Seema Nagpal, et al. CT258 Link [AACR 2021][TiP][CNS]
127

Drug loaded nanoparticle targeting of pancreatic cancer using Tumor Treating Fields (TTFields)

AACR 2021
Preshita Prafulla Desai, Sunil Prabhu. LB023 Link [AACR 2021]
128

Long-term application of TTFields in anaplastic astrocytoma - a case study

AACR 2021 Case study CNS
Darko Markovic. LB064 Link [AACR 2021][Case study][CNS]
129

Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial

WCLC 2020 TiP CNS
MP Mehta, V Gondi, P Brown, M Ahluwalia. P19.06 Link [WCLC 2020][TiP][CNS]
130

Radiological response to TTFields plus chemotherapy for malignant pleural mesothelioma from the phase 2 STELLAR trial

WCLC 2020 Clinical trial MPM
F Grosso, GL Ceresoli. P24.08 Link [WCLC 2020][Clinical trial][MPM]
131

Pooled safety analysis of clinical trials delivering Tumor Treating Fields (TTFields) to the upper torso

WCLC 2020 Clinical trial Lung MPM
F Grosso, GL Ceresoli. P24.09 Link [WCLC 2020][Clinical trial][Lung][MPM]
132

Effectiveness of Tumor Treating Fields plus cisplatin/pemetrexed combination in mesothelioma, in vitro and in vivo

WCLC 2020 Preclinical study MPM
M Giladi, H Mumblat, A Martinez, M Munster, et al. P25.09 Link [WCLC 2020][Preclinical study][MPM]
133

Computational simulations on safety of Tumor Treating Fields delivered to the lungs in mesothelioma and NSCLC

WCLC 2020 Physics / Simulation Lung MPM
Z Bomzon, N Urman, A Naveh. P25.10 Link [WCLC 2020][Physics / Simulation][Lung][MPM]
134

Evaluation of the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies

WCLC 2020 Preclinical study
M Giladi, S Davidi, R Blatt, M Munster, et al. P25.11 Link [WCLC 2020][Preclinical study]
135

Tumor Treating Fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study

WCLC 2020 TiP Lung
T Leal, R Bueno, L Havel, J Ward. P82.01 Link [WCLC 2020][TiP][Lung]
136

Genetic markers correlated with progression-free survival times in glioblastoma patients undergoing treatment with Tumor Treating Fields

SNO 2020 Clinical trial CNS
Caitlin Monson, Megan Tipps, Kelsey Jackson, Meghan Tierney, Nilanjana Banerji, et al. BIOM-41 Link [SNO 2020][Clinical trial][CNS]
137

PTEN mutations predict benefit from Tumor-Treating Fields therapy in patients with recurrent glioblastoma

SNO 2020 Clinical trial CNS
Antonio Dono, Sonali Mitra, Takeshi Takayasu, Jay-Jiguang Zhu, Nitin Tandon, et al. BIOM-48 Link [SNO 2020][Clinical trial][CNS]
138

Therapeutic implications of conditional vulnerabilities caused by TTFields exposure in novel combination therapies for non-small cell lung cancer and brain metastases from non-small cell lung cancer

SNO 2020 Preclinical study
Narasimha Kumar Karanam, Michael Story. CBIO-01 Link [SNO 2020][Preclinical study]
139

Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic

SNO 2020 CNS
Peggy Frongillo, Melissa Shackelford, Lindsay Rain. COVD-04 Link [SNO 2020][CNS]
140

Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic: Expert consensus on use and experience

SNO 2020 CNS
Na Tosha Gatson, Jill S Barnholtz-Sloan, Jan Drappatz, Roger Henriksson, Andreas Hottinger, et al. COVD-17 Link [SNO 2020][CNS]
141

Combining the glioblastoma cell membrane-permeabilizing effect of Tumor Treating Fields (TTFields) with withaferin A (and other) chemotherapy

SNO 2020 Preclinical study CNS
Edwin Chang, Chirag Patel, Caroline Young, Thomas Flores, Yi Zeng, et al. CSIG-14 Link [SNO 2020][Preclinical study][CNS]
142

Innovative computational platform addresses prostaglandin E receptor 3 as the master regulator mediating resistance to Tumor Treating Fields in glioblastoma cells

SNO 2020 Preclinical study CNS
Dongjiang Chen, Son Le, Tarun Hutchinson, David Tran. CSIG-15 Link [SNO 2020][Preclinical study][CNS]
143

Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

SNO 2020 Clinical trial CNS
Ashley Ghiaseddin, Sonisha Warren, Annie Allen, Deborah Sampson, Dongjiang Chen, et al. CTIM-04 Link [SNO 2020][Clinical trial][CNS]
144

Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma

SNO 2020 Clinical trial CNS
Julia Kodysh, Alex Rubinsteyn, Ana Blazquez, John Mandeli, Nina Bhardwaj, et al. CTIM-17 Link [SNO 2020][Clinical trial][CNS]
145

Scalp sparing radiation with concurrent temozolomide and Tumor Treatment Fields (SPARE) for patients with newly diagnosed glioblastoma

SNO 2020 Clinical trial CNS
Ryan Miller, Andrew Song, Ayesha Ali, Voichita Bar-Ad, Nina Martinez, et al. CTNI-21 Link [SNO 2020][Clinical trial][CNS]
146

A prospective, observational study evaluating the safety and quality of life of Tumor Treating Fields in Chinese glioblastoma patients

SNO 2020 RWE CNS
Kevin Wong, Tao Jiang CTNI-28 Link [SNO 2020][RWE][CNS]
147

A phase II trial of Tumor Treating Fields (TTFields) concomitant with radiosurgery for the treatment of recurrent, bevacizumab-naïve glioblastoma

SNO 2020 TiP CNS
Maciej Harat, Maciej Blok, Magda Adamczak-Sobczak, Pawel Szymanski, Iza Miechowicz, et al. CTNI-46 Link [SNO 2020][TiP][CNS]
148

First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields)

SNO 2020 RWE CNS
Christian Mawrin. CTNI-59 Link [SNO 2020][RWE][CNS]
149

Efficacy of TTFields in elderly patients with newly diagnosed glioblastoma (GBM) – sub-group analysis of the EF-14 trial

SNO 2020 Clinical trial CNS
Zvi Ram, Chae-Yong Kim, Jay-Jiguang Zhu. CTNI-68 Link [SNO 2020][Clinical trial][CNS]
150

Long-term survival in glioblastoma patients after Tumor Treating Fields (TTFields) therapy

SNO 2020 Clinical trial CNS
Aaron Rulseh, Adam Derner, Jan Sroubek, Jan Klener, Josef Vymazal. CTNI-70 Link [SNO 2020][Clinical trial][CNS]
151

TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population

SNO 2020 RWE CNS
Oliver Bähr, Ghazaleh Tabatabai, Rainer Fietkau, Roland Goldbrunner, Martin Glas. CTNI-71 Link [SNO 2020][RWE][CNS]
152

Overall survival of newly diagnosed glioblastoma patients treated by standard therapy in comparison to standard therapy plus Tumor Treating Fields

SNO 2020 Clinical trial CNS
Aaron Rulseh, Adam Derner, Jan Sroubek, Jan Klener, Josef Vymazal. CTNI-73 Link [SNO 2020][Clinical trial][CNS]
153

Phase 3 TRIDENT trial: Concomitant radiation therapy (RT) and temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

SNO 2020 TiP CNS
Wenyin Shi, Lawrence Kleinberg, Suriya A Jeyapalan, Samuel Goldlust, Seema Nagpal, et al. CTNI-74 Link [SNO 2020][TiP][CNS]
154

EF-19, a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

SNO 2020 RWE CNS
Jay-Jiguang Zhu, Robert T O’Donnell, Samuel Goldlust, Zvi Ram. CTNI-77 Link [SNO 2020][RWE][CNS]
155

PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

SNO 2020 TiP CNS
Sied Kebir, Lazaros Lazaridis, Teresa Schmidt, Christoph Oster, Daniela Pierscianek, et al. CTNI-79 Link [SNO 2020][TiP][CNS]
156

Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with combined Wee1 or Chk1 inhibitors in glioblastoma cell lines

SNO 2020 Preclinical study CNS
Paul L G Slangen, Mark C de Gooijer, Mariska van Geldorp, Olaf van Tellingen, Gerben R Borst EXTH-31 Link [SNO 2020][Preclinical study][CNS]
157

Valproic acid enhances anti-proliferative effects of Tumor Treating Fields on patient-derived gliosarcoma cells in vitro

SNO 2020 Preclinical study CNS
Sharon Michelhaugh, Sandeep Mittal. EXTH-33 Link [SNO 2020][Preclinical study][CNS]
158

Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro

SNO 2020 Preclinical study
Tali Voloshin, Yaara Porat, Noa Kaynan, Anat Klein-Goldberg, Rom Paz, et al. EXTH-69 Link [SNO 2020][Preclinical study]
159

The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields)

SNO 2020 Preclinical study
Shiri Davidi, Roni Blat, Anna Shteingauz, Yaara Porat, Moshe Giladi, et al. EXTH-76 Link [SNO 2020][Preclinical study]
160

Dual activation of the cGAS-STING pathway and AIM2-induced pyroptosis by Tumor-Treating Fields produces anti-tumor immunity in glioblastoma

SNO 2020 Preclinical study CNS
Dongjiang Chen, Mathew Sebastian, Tarun Hutchinson, Ashley Ghiaseddin, Sonisha Warren, et al. IMMU-42 Link [SNO 2020][Preclinical study][CNS]
161

Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

SNO 2020 Physics / Simulation CNS
Jennifer De Los Santos, Smadar Arvatz, Oshrit Zeevi, Shay levi, Zeev Bomzon, et al. INNV-05 Link [SNO 2020][Physics / Simulation][CNS]
162

Effects of TTFields usage and duration of usage on cellularity and Ki67 distributions at autopsy

SNO 2020 CNS
Samuel Bobholz, Allison Lowman, Jennifer Connelly, Elizabeth Cochran, Wade Mueller, et al. INNV-10 Link [SNO 2020][CNS]
163

Impact of gender on Tumor Treating Fields compliance in patients with glioblastoma

SNO 2020 RWE CNS
Lauren Karpf, Sanjeev Chawla, Lisa Desiderio, Suyash Mohan. NCOG-26 Link [SNO 2020][RWE][CNS]
164

First health utilities of glioblastoma patients using TTFields treatment

SNO 2020 HEOR CNS
Gordon Chavez, Christina Proescholdt. NCOG-36 Link [SNO 2020][HEOR][CNS]
165

Tumor Treating Fields in meningioma

SNO 2020 CNS
Christian Mawrin. NCOG-52 Link [SNO 2020][CNS]
166

Changes in magnetic resonance imaging after proton boost therapy for glioblastoma with and without Tumor Treating Fields therapy

SNO 2020 CNS
Hanna Goett, Alexandra Jensen, Tobias Struffert, Eberhard Uhl, Marco Stein. NIMG-33 Link [SNO 2020][CNS]
167

Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma

SNO 2020 Case study CNS
Allison Lowman, Sarah Hurrell, Samuel Bobholz, Jennifer Connelly, Elizabeth Cochran, et al. NIMG-37 Link [SNO 2020][Case study][CNS]
168

The effect of cell confluence on the distribution of Tumor Treating Fields

SNO 2020 Physics / Simulation
Tal Marciano, Shay Levi, Zeev Bomzon. NIMG-58 Link [SNO 2020][Physics / Simulation]
169

Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy

SNO 2020 Physics / Simulation CNS
Oshrit Zeevi, Zeev Bomzon, Tal Marciano. NIMG-65 Link [SNO 2020][Physics / Simulation][CNS]
170

Comparison of symptom burden and associated impact on daily life in glioblastoma patients treated with and without Tumor Treating Fields

SNO 2020 RWE CNS
Megan Tipps, Meghan Tierney, Caitlin Monson, Kelsey Jackson, Nilanjana Banerji, et al. QOLP-13 Link [SNO 2020][RWE][CNS]
171

New therapeutic delivery methods for Tumor-Treating Fields for higher efficacy

SNO 2020 Physics / Simulation
Kristen Carlson, Zeev Bomzon, Jeffrey Arle. RBIO-04 Link [SNO 2020][Physics / Simulation]
172

Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial

SNO 2020 TiP CNS
Minesh Mehta, Vinai Gondi, Paul Brown, Manmeet Ahluwalia. RTID-01 Link [SNO 2020][TiP][CNS]
173

Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial

SNO 2020 TiP CNS
Nikola Mikic, Anders Korshøj. RTID-06 Link [SNO 2020][TiP][CNS]
174

Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolamide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM)

SNO 2020 TiP CNS
Rachel Grossman, Dror Limon, Felix Bokstein, Carmit Ben Harosh, Deborah Blumenthal, et al. RTID-12 Link [SNO 2020][TiP][CNS]
175

Long-lasting Tumor Treating Fields (TTFields) stimulation of glioblastoma primary culture damages preferentially fully differentiated cancer cells

SNO 2020 Preclinical study CNS
Stefania Castiglione, Matteo Ranucci, Gaetano Cannavale, Francesca Cianci, Ivan Verduci, et al. STEM-10 Link [SNO 2020][Preclinical study][CNS]
176

Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics

SNO 2020 Preclinical study CNS
Tali Voloshin, Rosa Schneiderman, Alexandra Volodin, Reuben Shamir, Noa Kaynan, et al. TAMI-04 Link [SNO 2020][Preclinical study][CNS]
177

Effectiveness and safety of Tumor Treating Fields (150 kHz) plus cisplatin or pemetrexed combination in mesothelioma: in vitro and in vivo findings

ASTRO 2020 Preclinical study MPM
H Mumblat, M Munster, R Schneiderman, Y Porat, et al. 2275 Link [ASTRO 2020][Preclinical study][MPM]
178

The impact of electric conductivity of tissues on the electric field intensity and power density during TTFields therapy for glioblastoma

ASTRO 2020 Physics / Simulation CNS
N Gentilal, P Miranda. 2670 Link [ASTRO 2020][Physics / Simulation][CNS]
179

Sensitivity of TTFields numerical simulations to model inaccuracies

ASTRO 2020 Physics / Simulation CNS
O Zeevi, A Naveh, Z Bomzon, T Marciano. 2752 Link [ASTRO 2020][Physics / Simulation][CNS]
180

Evidence that recurrence patterns of TTFields treated patients affect patient outcome: Post-hoc analysis of the randomized phase 3 EF-14 trial

ASTRO 2020 Clinical trial CNS
M Ballo, S Mohan, S Jeyapalan. 2772 Link [ASTRO 2020][Clinical trial][CNS]
181

A machine learning based approach for rapidly estimating Tumor Treating Fields distributions in the body

ASTRO 2020 Physics / Simulation CNS
R Shamir, Z Bomzon. 2775 Link [ASTRO 2020][Physics / Simulation][CNS]
182

A simulation-based method for planning delivery of TTFields to brain tumors

ASTRO 2020 Physics / Simulation CNS
E Federov, Z Bomzon, T Marciano, R Shamir, et al. 2778 Link [ASTRO 2020][Physics / Simulation][CNS]
183

Tumor Treating Fields disrupt the CDK-E2F-Rb axis: Implications for the use of radiation and targeted agents against E2F and CDK4/6 during TTFields treatment

ASTRO 2020 Preclinical study Lung
NK Karanam, MD Story. 3226 Link [ASTRO 2020][Preclinical study][Lung]
184

Safety and effectiveness of Tumor Treating Fields (TTFields; 150 kHz) and sorafenib combination treatment in hepatocellular carcinoma in vitro and in vivo

ASTRO 2020 Preclinical study Liver
T Voloshin, S Davidi, C Tempel-Brami, M Munster, et la. 3510 Link [ASTRO 2020][Preclinical study][Liver]
185

Updated safety and feasibility study of concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma

ASTRO 2020 Clinical trial CNS
R Grossman, F Bokstein, D Blumenthal, D Limon, et al. 3551 Link [ASTRO 2020][Clinical trial][CNS]
186

Global Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

ASTRO 2020 RWE CNS
W Shi, DT Blumenthal, NA Oberheim Bush, S Kebir, et al. 3622 Link [ASTRO 2020][RWE][CNS]
187

EF-19: A post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

ASTRO 2020 RWE CNS
JJ Zhu, RT O'Donnell, Z Ram. 3624 Link [ASTRO 2020][RWE][CNS]
188

Developing a radiotherapy workflow for glioblastoma patients treated in presence of Tumor Treating Fields arrays

ASTRO 2020 Physics / Simulation CNS
M Sharma, SE Braunstein. 3646 Link [ASTRO 2020][Physics / Simulation][CNS]
189

Efficacy of Tumor Treating Fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase 3 EF-14 trial

ASTRO 2020 Clinical trial CNS
Z Ram, JJ Zhu. 3700 Link [ASTRO 2020][Clinical trial][CNS]
190

The long tail problem: novel parametric methods still underestimate long-term conditional survival in glioblastoma

ASTRO 2020 HEOR CNS
G Chavez, C Proescholdt, G Lavy-Shahaf. 3823 Link [ASTRO 2020][HEOR][CNS]
191

A phase III trial of Tumor Treating Fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3

ESMO 2020 TiP Pancreas
VJ Picozzi, T Macarulla Mercadé, PA Philip, CR Becerra, et al. 1567TiP Link [ESMO 2020][TiP][Pancreas]
192

Clinical outcomes of the combination of bevacizumab and TTFields in patients with recurrent glioblastoma: Results of a phase II clinical trial

ASCO 2020 Clinical trial CNS
Jaleh Fallah, Rekha T. Chaudhary, Lisa R. Rogers, et al. 2537 Link [ASCO 2020][Clinical trial][CNS]
193

Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

ASCO 2020 RWE CNS
Wenyin Shi, Deborah T Blumenthal, Nancy Ann Oberheim Bush, Seid Kebir, et al. 2542 Link [ASCO 2020][RWE][CNS]
194

Tumor Treating Fields effects on the blood-brain barrier in vitro and in vivo

ASCO 2020 Preclinical study CNS
Ellaine Salvador, Almuth Kessler, Julia Hoermann, Dominik Domroese, et al. 2551 Link [ASCO 2020][Preclinical study][CNS]
195

Updated safety/feasibility study of concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma

ASCO 2020 Clinical trial CNS
Rachel Grossman, Felix Bokstein, Deborah T. Blumenthal, Dror Limon, et al. e14535 Link [ASCO 2020][Clinical trial][CNS]
196

EF-19, a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

ASCO 2020 RWE CNS
Jay-Jiguang Zhu, Robert O'Donnell, Zvi Ram. e14536 Link [ASCO 2020][RWE][CNS]
197

Efficacy of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase III EF-14 trial

ASCO 2020 Clinical trial CNS
Zvi Ram, Chae-Yong Kim, Jay-Jiguang Zhu. e24019 Link [ASCO 2020][Clinical trial][CNS]
198

Compatibility of topical agents with Tumor Treating Fields (TTFields) for treatment of associated skin events in glioblastoma (GBM)

ASCO 2020 Preclinical study CNS
Moshe Giladi, Mario E. Lacouture, Uri Weinberg, Zeev Bomzon, et al. e24126 Link [ASCO 2020][Preclinical study][CNS]
199

Phase III TRIDENT trial: Radiation and temozolomide +/- Tumor Treating Fields in newly diagnosed glioblastoma

ASCO 2020 TiP CNS
Wenyin Shi, Lawrence Kleinberg, Suriya A Jeyapalan, Samuel Aaron Goldlust, et al. TPS2580 Link [ASCO 2020][TiP][CNS]
200

TTFields dose distribution alters tumor growth patterns: An imaging-based analysis of the randomized phase 3 EF-14 trial

AACR 2020 Clinical trial CNS
Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf. 44 Link [AACR 2020][Clinical trial][CNS]
201

Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint

AACR 2020 Preclinical study
Paul Slangen, Mariska van Geldorp, Mark de Gooijer, Olaf van Tellingen, et al. 92 Link [AACR 2020][Preclinical study]
202

What electric field strength is necessary for maximum Tumor-Treating Fields efficacy

AACR 2020 Physics / Simulation
Kristen W. Carlson, Jack A. Tuszynski, Socrates Dokos, Nirmal Paudel, et al. 472 Link [AACR 2020][Physics / Simulation]
203

Proteomic analysis of lung cancer cells exposed to Tumor Treating Fields identified the dysregulation of the E2F-Rb-CDK4/6 axis rendering tumor cells susceptible to novel combination therapies that target CDK4/6 and/or E2F

AACR 2020 Preclinical study Lung
Narasimha Kumar Karanam, Sivaramakrishna Yadavalli, Michael Story, et al. 559 Link [AACR 2020][Preclinical study][Lung]
204

In vitro and in vivo evidence for the safety and efficacy of Tumor Treating Fields (TTFields) in combination with sorafenib

AACR 2020 Preclinical study Liver
Shiri Davidi, Catherine Tempel-Brami, Mijal Munster, Anna Shteingauz, et al. 572 Link [AACR 2020][Preclinical study][Liver]
205

Efficacy of Tumor Treating Fields (TTFields) in combination with cisplatin or pemetrexed for the treatment of mesothelioma in vitro and in vivo

AACR 2020 Preclinical study MPM
Mijal Munster, Helena Mumblat, Shiri Davidi, Rosa Schneiderman, et al. 573 Link [AACR 2020][Preclinical study][MPM]
206

In vitro TTFields enhance the response to temozolomide or radiation in GBM cells from a newly diagnosed patient

AACR 2020 Preclinical study CNS
Sharon K. Michelhaugh, Sandeep Mittal. 574 Link [AACR 2020][Preclinical study][CNS]
207

Tumor Treating Fields (TTFields) elicit an anti-tumor immune response and in combination enhance anti-PD-1 treatment efficacy

AACR 2020 Preclinical study
Noa Kaynan, Tali Voloshin, Shiri Davidi, Yaara Porat, et al. 956 Link [AACR 2020][Preclinical study]
208

Overall survival of glioblastoma patients treated by standard therapy in comparison to standard therapy plus Tumor Treating Fields

AACR 2020 RWE CNS
Aaron Rulseh, Adam Derner, Jan Sroubek, Jan Klener, et al. 2038 Link [AACR 2020][RWE][CNS]
209

Cancer cell lines meta-analysis according to both short-term and long-term responses to Tumor Treating Fields (TTFields)

AACR 2020 Preclinical study
Kerem Wainer Katsir, Gitit Lavy Shahaf, Moshe Giladi, Rosa S. Schneiderman, et al. 2411 Link [AACR 2020][Preclinical study]
210

The inovivo system: A novel in vivo tool for the application of Tumor Treating Fields (TTFields) to mice

AACR 2020 Preclinical study
Shiri Davidi, Roni Blat, Anna Shteingauz, Sara Gerstein, et al. 2740 Link [AACR 2020][Preclinical study]
211

Combined in vitro TTFields and paclitaxel reduce proliferation and clonogenicity in non-small cell lung cancer (NSCLC) cells from a patient previously treated with standard-of-care

AACR 2020 Preclinical study Lung
Sharon K. Michelhaugh, Sandeep Mittal. 5254 Link [AACR 2020][Preclinical study][Lung]
212

Influence of the thermal and electric properties of biological tissues on the maximum temperature during TTFields therapy

AACR 2020 Physics / Simulation CNS
Nichal Gentilal, Pedro Cavaleiro Miranda. 5484 Link [AACR 2020][Physics / Simulation][CNS]
213

Transducer array layouts for treating head and neck cancer with TTFields

AACR 2020 Physics / Simulation Head & neck
Ze'ev Bomzon, Ariel Naveh, Yissachar Abraham. 5497 Link [AACR 2020][Physics / Simulation][Head & neck]
214

The influence of computational model inaccuracies on calculated electric field distributions when simulating TTFields therapy

AACR 2020 Physics / Simulation CNS
Ze'ev Bomzon, Ariel Naveh, Oshrit Ze'evi, Hadas S. Hershkovich. 5498 Link [AACR 2020][Physics / Simulation][CNS]
215

Co-activation of STING pathway and immunogenic cell death by Tumor Treating Fields produces effective antitumor immunity in glioblastoma

AACR 2020 Preclinical study CNS
Dongjiang Chen, Nagheme Thomas, Jie Ren, Son Le, et al. 5524 Link [AACR 2020][Preclinical study][CNS]
216

Tumor Treating Fields (TTFields) induce cancer cell permeability in vitro

AACR 2020 Preclinical study
Tali Voloshin, Yaara Porat, Noa Kaynan, Anat Klein-Goldberg, et al. 5848 Link [AACR 2020][Preclinical study]
217

HDAC6 inhibitors may enhance TTFields toxicity to glioma cells by altering primary cilia

AACR 2020 Preclinical study CNS
Ping Shi, Reemsha Basrai, Alice Cheng, Neil Kalaria, et al. 6203 Link [AACR 2020][Preclinical study][CNS]
218

Blood brain barrier opening by TTFields: a future CNS drug delivery strategy

AACR 2020 Preclinical study CNS
Ellaine Salvador, Almuth F. Kessler, Julia Hörmann, Malgorzata Burek, et al. 6251 Link [AACR 2020][Preclinical study][CNS]
219

Combining the glioblastoma cell membrane-permeabilizing effect of Tumor Treating Fields with chemotherapy

AACR 2020 Preclinical study CNS
Edwin Chang, Chirag Patel, Caroline J. Young, Thomas Anthony Flores, et al. 6258 Link [AACR 2020][Preclinical study][CNS]
220

Effects of tumor treating fields (TTFields) on dendritic cells functionality

AACR 2020 Preclinical study
Tali Voloshin, Shiri Davidi, Noa Kaynan, Rosa Schneiderman, et al. 6662 Link [AACR 2020][Preclinical study]
221

Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

AACR 2020 Clinical trial CNS
Nikola Mikic, Anders R. Korshøj, Slavka Lukacova, et al. CT103 Link [AACR 2020][Clinical trial][CNS]
222

PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

AACR 2020 Clinical trial CNS
Sied Kebir, Lazaros Lazaridis, Teresa Schmidt, Christoph Oster, et al. CT106 Link [AACR 2020][Clinical trial][CNS]
223

Optimizing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial

AACR 2020 TiP CNS
Nikola Mikic, Anders R. Korshøj. CT184 Link [AACR 2020][TiP][CNS]
224

HEPANOVA: Interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)

AACR 2020 Clinical trial Liver
Eleni Gkika, Thomas Brunner, Robert Thimme, Anca-Ligia Grosu. CT186 Link [AACR 2020][Clinical trial][Liver]
225

Concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A safety and feasibility study

AACR 2020 Clinical trial CNS
Felix Bokstein, Deborah Blumenthal, Dror Limon, Carmit Ben Harosh, et al. CT206 Link [AACR 2020][Clinical trial][CNS]
226

EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM)

AACR 2020 RWE CNS
Jay-Jiguang Zhu, Robert T. O'Donnell, Zvi Ram. CT211 Link [AACR 2020][RWE][CNS]
227

Efficacy of TTFields in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the EF-14 trial

AACR 2020 Clinical trial CNS
Zvi Ram, Jay-Jiguang Zhu. CT219 Link [AACR 2020][Clinical trial][CNS]
228

Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

AACR 2020 RWE CNS
Wenyin Shi, Deborah T. Blumenthal, Nancy Ann Oberheim Bush, Sied Kebir, et al. LB-167 Link [AACR 2020][RWE][CNS]
229

Impact of innovative educational approaches to enhance patient and caregiver understanding of Tumor Treating Fields (TTFields) for glioblastoma implications for outcomes

AACR 2020 CNS
Peggy M. Frongillo, Melissa Shackelford, Jeanine Certo. LB-255 Link [AACR 2020][CNS]
230

Budget impact analysis of TTFields + platinum-based therapy for first-line malignant pleural mesothelioma

AACR 2020 HEOR MPM
Bruce C. Wang, Wesley Furnback, Christina Proescholdt, Gordon Chavez. LB-291 Link [AACR 2020][HEOR][MPM]
231

Immunomodulatory effects of Tumor Treating Fields (TTFields) on colon cancer models

ASCO GI 2020 Preclinical study Colorectum
Tali Voloshin, Noa Kaynan, Shiri Davidi, Yaara Porat, et al. 136 Link [ASCO GI 2020][Preclinical study][Colorectum]
232

Tumor Treating Fields (TTFields; 150 kHz) and FOLFOX combination treatment effects on gastric cancer in vitro

ASCO GI 2020 Preclinical study Stomach
Einav Zeevi, Karnit Gotlib, Rosa S Schneiderman, Mijal Munster, et al. 406 Link [ASCO GI 2020][Preclinical study][Stomach]
233

In vitro and in vivo efficacy and safety of Tumor Treating Fields (TTFields) and sorafenib combination in hepatocellular carcinoma

ASCO GI 2020 Preclinical study Liver
Shiri Davidi, Catherine Tempel-Brami, Mijal Munster, Karnit Gotlib, et al. 551 Link [ASCO GI 2020][Preclinical study][Liver]
234

A multicenter phase II trial of Tumor Treating Fields plus chemotherapy for first-line treatment of gastric adenocarcinoma

ASCO GI 2020 TiP Stomach
Jin Li, Winnie Yeo, Ka-On Lam. TPS474 Link [ASCO GI 2020][TiP][Stomach]
235

Phase II HEPANOVA trial of Tumor Treating Fields concomitant with sorafenib for advanced hepatocellular carcinoma

ASCO GI 2020 TiP Liver
Anca Grosu, Eleni Gkika, Thomas B. Brunner, Robert Thimme. TPS603 Link [ASCO GI 2020][TiP][Liver]
236

PANOVA-3: A phase III study of Tumor Treating Fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC)

ASCO GI 2020 TiP Pancreas
Vincent J. Picozzi, Teresa Macarulla, Philip Agop Philip, Carlos Roberto Becerra, et al. TPS792 Link [ASCO GI 2020][TiP][Pancreas]
Back to Top